Background In COVID-19, severe disease course such as need of intensive care unit (ICU)
as well as development of mortality is mainly due to cytokine storm. In this study, we aimed …

Introduction Severe COVID-19 cases have a detrimental hyper-inflammatory host response
and different cytokine-blocking biologic agents were explored to improve outcomes …

Introduction Hyperinflammatory state has a role in the pathogenesis of COVID‐19. Anakinra
could reduce inflammation and help to combat the condition. In this study, we aimed to …

Background and objective The most important presentation of COVID-19 is hyper
inflammatory condition and cytokine storm that occurs due to excessive increase of the …

Background The global COVID-19 pandemic led to substantial clinical and economic
outcomes with catastrophic consequences. While the majority of cases has mild to moderate …

Objective We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor,
could improve outcome in moderate COVID-19 patients. Methods In this controlled, open …

The role of immunomodulatory agents in the treatment of hospitalized patients with COVID-
19 has been of increasing interest. Anakinra, an interleukin-1 inhibitor, has been shown to …

Importance COVID-19 pneumonia is often associated with hyperinflammation. The efficacy
and safety of anakinra in treating patients with severe COVID-19 pneumonia and …

Acute respiratory distress syndrome and cytokine release syndrome are the major
complications of coronavirus disease 2019 (COVID-19) associated with increased mortality …

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus
disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 …